Absorption Systems Named a Finalist for ‘Emerging Life Sciences Company’ Award
Absorption Systems, a leading preclinical ADMET contract research organization for drugs and medical devices, was named a finalist for the "Emerging Life Sciences Company of the Year" for the 18th Annual Enterprise Awards in recognition of their CellPort Technologies testing platform.
Exton, PA (PRWEB) April 21, 2011
Absorption Systems, a leader in testing drugs for ADMET (absorption, distribution, metabolism, excretion and toxicity), today announced that the company has been selected as a finalist for the “Emerging Life Science Company of the Year” award which is part of the Greater Philadelphia Alliance for Capital and Technologies (PACT) 18th annual Enterprise Awards program.
“We are honored to be considered by the esteemed panel of judges as one of the premier emerging life science companies in the Philadelphia region,” said Patrick M. Dentinger, president and chief executive officer of Absorption Systems. “This distinction acknowledges the fast-paced growth and impeccable reputation Absorption Systems has earned since our company’s inception. None of this would have been possible without the talented individuals who make up our company. It is their focus on customer service and their sincere commitment to bringing safer drugs to market that has made it possible for Absorption Systems to stand out among the many nominations submitted for this award.”
The Enterprise Awards, presented by PACT in partnership with PricewaterhouseCoopers LLP, remain the region’s most prestigious business honors for technology and life sciences companies, executives, and entrepreneurs. Attracting more than 1,200 prominent business leaders, the Enterprise Awards black-tie gala celebrates outstanding achievement, innovation, and success in the Greater Philadelphia region. Winners in each category will be announced at the Enterprise Awards annual gala on Wednesday, May 4, at the Hilton Philadelphia City Avenue.
About Absorption Systems
Absorption Systems, founded in 1996, assists pharmaceutical and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs and medical devices. The company’s mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. The CellPort TechnologiesÂ® platform, a suite of human cell-based tests systems for drug transporter characterization, exemplifies Absorption Systems’ commitment to innovation and is soon to be an industry standard for in vitro drug interaction assessment. Absorption Systems has facilities near Philadelphia, PA, and San Diego, CA, and serves customers throughout the world. For information on the company’s comprehensive contract services and applied research programs, please visit http://www.absorption.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/4/prweb8330420.htm